Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer, Rare Disease Drugs To Be Covered As China Expands Reimbursement

Executive Summary

China's national reimbursement drug list will undergo a much anticipated expansion in 2019, and therapies for cancer, pediatric and rare conditions from international firms including Roche and Actellion are likely to receive long-awaited coverage.

You may also be interested in...



Hello NMPA: New English Website For China's Regulator, Inspection Scheme Bolstered

China's main drug regulatory agency is hoping to tell its story to the world via a new English website, while the vaccines and other sectors are poised to see increasing quality inspections as the country builds up a new two-level scheme. Provincial reimbursement lists are also being halted.

Calm Before The Storm: Pharma Opens 2019 With A Bang In China

Products old, new and reimbursed were the driving force for foreign drug firms including AstraZeneca, Merck and Pfizer and Sanofi to smash growth in China in the first quarter.

Choose Carefully For China Drug Development Success: White Paper

By avoiding crowded space and focusing instead on therapeutic areas with large potential, China remains attractive for drug developers, notes a recent white paper from investment bank China E-Capital.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124911

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel